Navigation Links
ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will hold a conference call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 p.m. Eastern) to review financial results for the second quarter and provide an update on its business.

Individuals interested in listening to the conference call may do so by dialing (866) 305-6438 for domestic callers, or (706) 679-7161 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.adventrx.com.

A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 23355569. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

About ADVENTRX

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose product candidates are designed to improve the safety of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Grace Century, ... and healthcare projects, announces the addition of Dr. ... to its advisory team. Dr. Siddiqui will provide further ... , A graduate of University College Medical School ... degreed in medicine in 2001. With further certification as ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... Md., April 8 Micromet, Inc. (Nasdaq: ... proprietary antibodies for the treatment of cancer, inflammation ... data in the peer-reviewed Journal of Immunotherapy (1) ... antibody binding to carcinoembryonic antigen (CEA) and to ...
... Inc., a Research Management Organization (RMO), has been selected ... Showcase during BIOZONA 2009 - Arizona,s Annual Bioscience Industry ... in Phoenix, Arizona.Matthew B. Wiener, PharmD, COO and Founder ... of the conference. The presentation will cover topics ...
... The following release is being issued by ... http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ) WHAT: ... of medical science and discovery in the United ... to maintaining America,s leadership in medical innovation. ...
Cached Biology Technology:Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for 'Best and Brightest Forum on Medical Innovation' 2
(Date:10/25/2014)... This report covers the specifics of microRNA (miRNA) as ... of research due to its versatility and stability, properties ... components. miRNA,s non-coding nature and ability to affect genetic ... a biomarker for a variety of diseases. This prompted ... advancement in therapeutic development. Furthermore there are a number ...
(Date:10/22/2014)... Oct. 20, 2014  Leading identity analyst firm Acuity ... of the world,s population will have a chip-based National ... Europe . Asia , with ... accounting for more than 60% of all National eID ... report  -- "The Global National eID Industry ...
(Date:10/18/2014)... patients with undiagnosed, suspected genetic conditions, a certain type ... molecular diagnostic yield than traditional molecular diagnostic methods, according ... study is being released to coincide with the American ... which sequences the protein­coding region of the genome (the ... a cell or organism), has been rapidly applied in ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... Molecular Biology Laboratory (EMBL) have generated a digital zebrafish ... vertebrate. With a newly developed microscope scientists could for ... 24 hours in the life of a zebrafish. The ... the embryo. The study, published in the current online ...
... vitamin D, once linked to only bone diseases such as ... in contributing to overall human health, emphasizes UC Riverside,s ... In a paper published in the August issue of the ... identifies vitamin D,s potential for contributions to good health in ...
... cornerstone of Frontiers in Optics 2008 (FiO), the 92nd ... Oct. 19-23 at the Riverside Convention Center in Rochester, ... Science XXIV, the annual meeting of the American Physical ... obtaining a badge to attend the meeting should contact ...
Cached Biology News:Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Where optics meets medicine 2Where optics meets medicine 3Where optics meets medicine 4Where optics meets medicine 5Where optics meets medicine 6Where optics meets medicine 7